IRIS - Res&Arch Institutional Research Information System - Research & Archive

SPORTOLETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.423
EU - Europa 1.928
AS - Asia 570
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 2
Totale 4.938
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.414
IT - Italia 745
IE - Irlanda 573
HK - Hong Kong 274
VN - Vietnam 140
SE - Svezia 123
UA - Ucraina 117
CN - Cina 97
FI - Finlandia 86
RU - Federazione Russa 59
DE - Germania 53
RO - Romania 47
GB - Regno Unito 28
FR - Francia 27
BE - Belgio 22
CH - Svizzera 15
TR - Turchia 14
AT - Austria 11
UZ - Uzbekistan 11
SG - Singapore 9
NL - Olanda 7
CI - Costa d'Avorio 6
IN - India 6
PL - Polonia 6
CA - Canada 4
IR - Iran 4
SC - Seychelles 4
CZ - Repubblica Ceca 3
GR - Grecia 3
LB - Libano 3
MX - Messico 3
PH - Filippine 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EU - Europa 2
IL - Israele 2
JP - Giappone 2
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
EC - Ecuador 1
ES - Italia 1
GH - Ghana 1
ID - Indonesia 1
IM - Isola di Man 1
IQ - Iraq 1
KH - Cambogia 1
KR - Corea 1
PA - Panama 1
TW - Taiwan 1
Totale 4.938
Salva come PNG Salva come JPEG
Città #
Chandler 594
Dublin 567
San Mateo 384
Perugia 377
Hong Kong 274
Dong Ket 140
Altamura 131
Medford 107
Princeton 105
Lawrence 101
Ann Arbor 81
Wilmington 66
Andover 63
Jacksonville 57
Beijing 50
Bucharest 43
Helsinki 36
Des Moines 27
Dearborn 26
New York 25
Redmond 25
Rome 24
Los Angeles 23
Brussels 22
Foligno 22
San Paolo di Civitate 20
Houston 19
Norwalk 18
Redwood City 17
Izmir 14
Saint Petersburg 14
Assisi 12
Menlo Park 12
Ashburn 9
Woodbridge 9
Collazzone 8
Falls Church 8
Vienna 8
Boardman 7
Shanghai 7
Abidjan 6
Cambridge 6
Chicago 6
Guangzhou 6
Nanning 6
Shenzhen 6
Singapore 6
Terni 6
Fairfield 5
Fremont 5
Amsterdam 4
Bastia 4
Bologna 4
Frankfurt Am Main 4
Milan 4
Paris 4
San Diego 4
Tappahannock 4
Campobasso 3
Macerata 3
Moscow 3
Osimo 3
Rohtak 3
Anaheim 2
Ancona 2
Auburn Hills 2
Baotou 2
Changsha 2
Dallas 2
Davao City 2
Den Haag 2
Hefei 2
Jinan 2
Lappeenranta 2
Lausanne 2
Melissa 2
Mirano 2
Montréal 2
Nanjing 2
Rocca Di Papa 2
Sassari 2
Selargius 2
Timisoara 2
Tokyo 2
West Jordan 2
Zero Branco 2
Zgierz 2
Acerra 1
Acireale 1
Allentown 1
Apo 1
Basra 1
Battipaglia 1
Bekasi 1
Belgioioso 1
Belluno 1
Butuan 1
Catania 1
Chengdu 1
Civitanova Marche 1
Totale 3.718
Salva come PNG Salva come JPEG
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 120
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 108
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 102
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 97
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 86
Mesenchymal cells: a vehicle for gene therapy 84
Wnt/beta-Catenin Signaling Induces Integrin alpha 4 beta 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice 83
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 82
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 81
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 80
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 78
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis 77
The radiosensitizer Silver nanoparticles effects are prevent to ion channel blocker DIDS in U251 human glioblastoma cell line. 76
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 75
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 74
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 72
Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice 70
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 66
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 66
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 65
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 65
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 64
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 63
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 62
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 60
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 60
T regulatory cell separation for clinical application. 60
Mutant NPM1 Maintains the Leukemic State through HOX Expression 60
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 59
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 58
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 58
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 58
BRAF mutations in hairy-cell leukemia. 57
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 57
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 57
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 56
Isolation and characterization of a new human T regulatory cell subset from peripheral blood CD4+ T lymphocyte 53
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 53
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 52
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. 51
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 50
Glucocorticoidi-Induced TNFR family Related gene (GITR) enhances dendritic cell activity 50
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. 50
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 50
Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 49
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 48
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 48
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 47
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 47
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice 46
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 46
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 45
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 45
Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. 45
BCOR gene alterations in hematological diseases 45
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 44
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 43
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 42
NPM1-mutated acute myeloid leukemia: from bench to bedside 40
Richter's transformation in the heart 39
Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. 38
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 38
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 38
null 37
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. 37
Mesenchymal cells recruit and regulate T regulatory cells. 36
A scale of "bad" co-mutations in NPM1-driven AML 36
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 36
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 35
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells 35
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 35
Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia. 35
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 34
Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions 33
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 32
The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model 31
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL 31
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. 30
Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse 30
NOTCH and Graft-Versus-Host Disease 30
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 30
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 30
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 29
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 29
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 29
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 27
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 27
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study 27
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 26
Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics 26
The landscape of BRAF transcript and protein variants in human cancer. 26
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 26
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 26
How does the NPM1 mutant induce leukemia? 24
The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. 24
A DYSREGULATED, DRUGGABLE PP2A/AKT/GSK3 beta AXIS SUSTAINS NOTCH1 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 23
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 23
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 23
The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein 20
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 20
Totale 4.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.786
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.786
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201930 0 0 0 0 0 0 0 0 0 0 29 1
2019/2020292 10 6 19 7 18 27 24 15 34 107 8 17
2020/2021586 9 23 14 25 165 31 37 29 47 21 35 150
2021/20221.312 48 376 9 44 26 9 18 226 30 138 210 178
2022/20231.946 111 371 18 183 140 195 11 85 708 8 81 35
2023/2024631 41 81 53 35 6 24 284 10 54 32 11 0
Totale 5.293